Background: Immune checkpoint inhibitors benefit the patients with various types of cancer and prolonged duration of treatment. As the number of patients received immune checkpoint inhibitors has increased, the experience of immune-related adverse events (irAEs) has been accumulated in clinical practice. However, irAEs include various types of pathology and make it difficult to understand and appropriately assess the situation. Despite the fact of the common clinical use of immune checkpoint inhibitors, the incidence of irAEs and the appropriate approach have not been fully elucidated. To overcome this situation, a support team for irAEs was organized in Chiba University Hospital, Immunotherapy Professional Action Team (ImPACT). Objectives: To perceive the actual situation of irAEs in clinical practice.
Methods: All patients, except for the patients enrolled in clinical trials, received immune checkpoint inhibitors since August 2014 were analyzed retrospectively. Results: Fifty-four patients received nivolumab and three received ipilimumab in our institution. In the patients discontinued from immune checkpoint inhibitors, irAEs accounts for about 20% of the reasons for discontinuation. Although almost all of the patients promptly received the support of ImPACT, a few patients experienced severe and critical irAEs. Subsequent assesment will be additionally analyzed. This study is part of a global risk analysis of our cytotoxic process and focuses on administration of chemotherapy. The main goal is to identify, estimate, classify and handle the highlighted risks. Another objective is to standardize the practice of chemotherapy administration. We chose the method of Preliminary Risk Analysis (PRA). The group of experts consisted of a physician, a nurse supervisor, a quality director, a pharmacist, a nurse, an auxiliary nurse and a pharmacist resident. Four meetings of 2 hours were necessary. The process was divided in 4 steps: medical validation (VAL), administration set preparation (PRE), administration (ADM) and supervision of the patient (SUP). Hazard map was established from scientific literature and experience. The study of the interaction between each hazard and each sub-phase identified 88 dangerous situations (DS), 48 with a priority index (PI) 1, to handle immediately, 25 with PI 2, to handle in a second time and 15 with PI 10, to handle with an another group. Gravity and frequency scales were made on 5 levels. Criticality (C) scale characterizes the risk acceptation: C1 tolerable, C2 tolerable under control and C3 intolerable. Criticality matrix is the classification of the risk depending on gravity and frequency. 48 DS with a PI 1 produced 85 risks scenarios. Initially, 42 were in C1, 37 in C2 and 6 in C3. Human and technique were the main hazards with 41 and 51% of risks scenarios. Corrective measures focus on personnel (e.g nurse training plan) and technical support (e.g clearer labelling). Residual risk management rests on audits and monitoring adverse events. The study allowed to set up measures of reduction and control of risks during chemotherapy administration. Among these measures, structuration and traceability of nurses' training are particularly important and were pointed out to inspectors of the High Health Authority. To perpetuate the ongoing work, corrective measures must be evaluated. 
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